суббота, 16 января 2016 г.

What Pharma/Biotech Investors Need To Know About Adaptive Trials

What Pharma/Biotech Investors Need To Know About Adaptive Trials


The FDA allows for adaptive drug trials during which key protocols may be altered during the course of the trial depending on interim results. Investors concerned with pharmaceutical or biotech drug development, from early to late stages, need to be aware of the benefits and risks of adaptive trials because their use and interpretation can impact corporate valuations.



from Biotech News